Abstract: A detection apparatus having a read head including a plurality of microfluorometers positioned to simultaneously acquire a plurality of the wide-field images in a common plane; and (b) a translation stage configured to move the read head along a substrate that is in the common plane. The substrate can be a flow cell that is included in a cartridge, the cartridge also including a housing for (i) a sample reservoir, (ii) a fluidic line between the sample reservoir and the flow cell; (iii) several reagent reservoirs in fluid communication with the flow cell, (iv) at least one valve configured to mediate fluid communication between the reservoirs and the flow cell; and (v) at least one pressure source configured to move liquids from the reservoirs to the flow cell. The detection apparatus and cartridge can be used together or independent of each other.

Abstract: The disclosure provides methods for predicting surface-presenting peptides using binding and surface-presentation characteristics. The method can include accessing a trained machine-learning model that is configured to generate an output that indicates an extent to which the one or more expression levels and the one or more peptide-presentation metrics are related in accordance with a population-level relationship between expression and presentation. For each peptide of the set of peptides for a tissue sample, a score can be determined using the machine-learning model and genomic and transcriptomic data corresponding to the peptide. The score is predictive of whether a corresponding peptide is a surface-presenting peptide that binds to an MHC molecule and is presented on a cell surface.

Abstract: Embodiments are generally directed to managing power consumption of powered devices. In some embodiments, the powered devices draw power from a common source of power, which is limited. Under certain circumstances, exceeding the power limits can cause interruption of power to one or more of the devices, thus introducing a source of communication failures. To ensure reliable communications, an attempt to increase a power consumption of a first powered device in a power group is first reviewed to determine if the increase will cause a supplied power of the group to exceed a maximum power of the group. If the increase will cause the maximum power to be exceeded, the increase is modified, in some circumstances, to fit within the maximum power level. Alternatively, power consumption of a lower priority device is reduced to accommodate the requested power consumption increase.

Abstract: An additive manufacturing system includes a laser array including a plurality of laser devices. Each laser device of the plurality of laser devices generates an energy beam for forming a melt pool in a powder bed. The additive manufacturing system further includes at least one optical element. The optical element receives at least one of the energy beams and induces a predetermined power diffusion in the at least one energy beam.

Abstract: Described herein are NLRP3 modulators and methods of utilizing NLRP3 modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

Abstract: One or more computing devices, systems, and/or methods are provided. A request for content associated with a device and/or a set of request information associated with the request for content may be received. A content item may be transmitted to the device. A set of client information associated with the device may be received. The set of client information may be analyzed to determine a fraudulence label associated with the request for content. Fraud detection information generated based upon the set of request information, the set of client information and/or the fraudulence label may be stored in a fraud detection database. A second request for content associated with a second device and/or a second set of request information associated with the second request for content may be received. A second fraudulence label may be determined based upon the second set of request information and/or the fraud detection database.

Abstract: A system and method including receiving a data model representation of a part, the data model representation including at least one layer of the part and inner and outer contours for the at least one layer; determining a hatch pattern for each layer of the at least one layer of the part, the hatch pattern for each layer being dependent on the inner and outer contours for each respective layer; generating a record of the determined hatch pattern for each layer, the record including locations for the hatch pattern for each layer; and saving the record of the determined hatch pattern for each layer of the part. In some aspects, the record of the determined hatch pattern for each layer of the part may be used in an additive manufacturing process.

Abstract: Compounds are provided having the structure of Formula (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein R1, R2, X1, X2, Y1, and Y2 are as defined herein. Such compounds function as thyromimetics and have utility for treating diseases such as neurodegenerative disorders and fibrotic diseases. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation.

Abstract: Methods for generating a composite biomarker that identifies a predicted level of responsiveness of a subject to a particular type of an immunotherapy treatment is provided. The method can include generating genomic metrics that represent one or more characteristics corresponding to one or more DNA sequences. The method can also include generating transcriptomic metrics represent one or more characteristics corresponding to a set of peptides that are translated from a corresponding RNA sequence of the one or more RNA sequences. The method can also include generating a composite biomarker score derived from the set of genomic metrics and the set of transcriptomic metrics. The method can also include determining, based on the composite biomarker score, a predicted level of responsiveness of the subject to a particular type of an immunotherapy treatment.

Abstract: A detection apparatus having a read head including a plurality of microfluorometers positioned to simultaneously acquire a plurality of the wide-field images in a common plane; and (b) a translation stage configured to move the read head along a substrate that is in the common plane. The substrate can be a flow cell that is included in a cartridge, the cartridge also including a housing for (i) a sample reservoir; (ii) a fluidic line between the sample reservoir and the flow cell; (iii) several reagent reservoirs in fluid communication with the flow cell, (iv) at least one valve configured to mediate fluid communication between the reservoirs and the flow cell; and (v) at least one pressure source configured to move liquids from the reservoirs to the flow cell. The detection apparatus and cartridge can be used together or independent of each other.

Abstract: One or more computing devices, systems, and/or methods are provided. Event information associated with a plurality of events may be identified. The plurality of events may be associated with first entities corresponding to a first entity type and second entities associated with a second entity type. A first network profile associated with the first entities and the second entities may be generated based upon the event information. An iterative process may be performed to identify a coalition network associated with fraudulent activity. The iterative process may include analyzing the first network profile to identify a first set of entities, of the first entities, that are related to an entity of the second entities, and/or analyzing the first network profile to identify a second set of entities, of the second entities, that are related to the first set of entities. Multiple iterations may be performed to identify the coalition network.

Abstract: Described herein are Janus kinase (JAK) inhibitors and methods of utilizing JAK inhibitors in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

Abstract: An additive manufacturing system includes a laser array including a plurality of laser devices. Each laser device of the plurality of laser devices generates an energy beam for forming a melt pool in a powder bed. The additive manufacturing system further includes at least one optical element. The optical element receives at least one of the energy beams and induces a predetermined power diffusion in the at least one energy beam.

Abstract: Described herein are N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl) carbamoyl)-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds of formula (I) wherein R1 is formulae (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX) and R2 is formulae (X) or (XI) as NLPR3 (pyrin domain-containing protein 3) modulators for the treatment of e.g. metabolic diseases (e.g. type 2 diabetes or obesity), liver diseases (e.g. NAFLD or cirrhosis), lung diseases (e.g. asthma or CORD), central nervous system diseases (e.g. Alzheimer's disease or multiple sclerosis), inflammatory or autoimmune diseases (e.g. rheumatoid arthritis or psoriasis), cardiovascular diseases (e.g. atherosclerosis or stroke). The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 67 to 90; examples 1 to 21; compounds 1 to 126; tables). An exemplary compound is e.g.

Abstract: A computer-implemented method for processing and/or analyzing nucleic acid sequencing data comprises receiving a first data input and a second data input. The first data input comprises untargeted sequencing data generated from a first nucleic acid sample obtained from a subject. The second data input comprises target-specific sequencing data generated from a second nucleic acid sample obtained from the subject. Next, with the aid of a computer processor, the first data input and the second data input are combined to produce a combined data set. Next, an output derived from the combined data set is generated. The output is indicative of the presence or absence of one or more polymorphisms of the first nucleic acid sample and/or the second nucleic acid sample.

Abstract: Embodiments are generally directed to managing power consumption of powered devices. In some embodiments, the powered devices draw power from a common source of power, which is limited. Under certain circumstances, exceeding the power limits can cause interruption of power to one or more of the devices, thus introducing a source of communication failures. To ensure reliable communications, an attempt to increase a power consumption of a first powered device in a power group is first reviewed to determine if the increase will cause a supplied power of the group to exceed a maximum power of the group. If the increase will cause the maximum power to be exceeded, the increase is modified, in some circumstances, to fit within the maximum power level. Alternatively, power consumption of a lower priority device is reduced to accommodate the requested power consumption increase.

Abstract: One or more computing devices, systems, and/or methods are provided. A request for content associated with a device and/or a set of request information associated with the request for content may be received. A content item may be transmitted to the device. A set of client information associated with the device may be received. The set of client information may be analyzed to determine a fraudulence label associated with the request for content. Fraud detection information generated based upon the set of request information, the set of client information and/or the fraudulence label may be stored in a fraud detection database. A second request for content associated with a second device and/or a second set of request information associated with the second request for content may be received. A second fraudulence label may be determined based upon the second set of request information and/or the fraud detection database.

Abstract: Described herein are Janus kinase (JAK) inhibitors of the Formula (I?): and methods of utilizing JAK inhibitors of the Formula (I?) in the treatment of diseases, disorders, or conditions. Also described herein are pharmaceutical compositions containing such compounds.

Abstract: A system for use in additively manufacturing an object. The system includes a powder bed configured for containment within a build chamber, wherein the powder bed is formed from a mixture of a build material and a bonding agent. The system also includes a heat source configured to selectively heat the powder bed to a temperature such that the build material is at least partially sintered together by the bonding agent. The heat source also selectively heats the powder bed to the temperature that maintains the build material in a solid state.